Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Scientists find new evidence on GSK vaccine link to narcolepsy

Wed, 01st Jul 2015 18:00

* GSK's Pandemrix shot linked to spike in narcolepsy cases

* Incurable disorder causes sleep attacks and nightmares

* Study finds link in flu protein found in H1N1 flu strainBy Kate Kelland, Health and Science Correspondent

LONDON, July 1 (Reuters) - Scientists investigating why aGlaxoSmithKline flu vaccine triggered narcolepsy in somepeople say they have the first solid evidence the rare sleepdisorder may be a so-called "hit-and-run" autoimmune disease.

The researchers were trying to find out why, of twodifferent flu vaccines widely deployed during the 2009/2010swine flu pandemic, only one -- GSK's Pandemrix -- was linkedwith a spike in cases of narcolepsy.

In a study published in the journal Science TranslationalMedicine, they said the answer could lie in a protein in theH1N1 flu strain found in high amounts in the GSK shot but atmuch lower levels in the other vaccine, Novartis' Focetria.

"It was a really exciting moment," Lawrence Steinman, aprofessor of neurology and neurological sciences who led thework at Stanford University, said of the finding.

A spokeswoman for GSK, whose Pandemrix vaccine was withdrawnfrom the market after the 2009/2010 pandemic, said the companywas aware of the study and would "review it carefully".

"We are actively conducting research into the observedassociation between Pandemrix and narcolepsy and the interactionthis vaccine might have had with other risk factors in thoseaffected," she said in an emailed comment.

Narcolepsy is an incurable, lifelong brain disorder thatdisrupts normal sleep-wake cycles and causes severe nightmaresand daytime sleep attacks that can strike at any time.

Scientists are not sure exactly what causes it, but thelatest research suggests it is a type of auto-immune disease,where the immune system misfires and mistakenly attacks thebody's own functions and organs.

Studies in countries where GSK's Pandemrix vaccine was usedin the 2009/2010 flu pandemic -- including Britain, Finland,Sweden and Ireland -- have found a significant rise in cases ofnarcolepsy in children.

Narcolepsy patients have been shown to have a loss offunction in "wakefulness" cells called hypocretin cells in oneof the brain's sleep centres.

In their study, Steinman's team found that H1N1 pandemic flucontains a protein whose structure partly mimics a portion of ahypocretin receptor in the brain. This H1N1 protein wascontained in both vaccines studied, but at much higher levels inGSK's Pandemrix than in Novartis' Focetria.

The scientists said they now believe the narcolepsy inpeople vaccinated with Pandemrix was caused by a so-called "hitand run" mechanism, in which high levels of the H1N1 proteinstimulated the production of large amounts of antibodies to boththe virus and the hypocretin receptor. (Editing by Larry King)

More News
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.